Dermatology Conference 2023 | Bangkok, Thailand

Comments

Post a Comment

Popular posts from this blog

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-;a novel, patient-tailored monoclonal antibody therapy-;showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet. source https://www.news-medical.net/news/20221212/Novel-monoclonal-antibody-therapy-shows-promising-results-in-patients-with-moderate-to-severe-atopic-dermatitis.aspx
Read more